莲芪胶囊联合肝动脉栓塞化疗治疗原发性肝癌的疗效观察  

Observation of Efficacy of the Lianqi Combined with Transcatheter Hepatic Arterial Chemoembolization in Treatment of Primary Liver Cancer

作　　者：白燕[1] 温俊邦[2] 

机构地区：[1]四川崇州市人民医院肿瘤科,崇州611200 [2]四川崇州市人民医院放射科,崇州611200

出　　处：《中国医药导刊》2014年第3期459-460,共2页Chinese Journal of Medicinal Guide

摘　　要：目的:探讨莲芪胶囊联合肝动脉栓塞化疗治疗原发性肝癌的临床疗效。方法:98例原发性肝癌患者,随机分为治疗组和对照组,各49例,两组均行肝动脉栓塞化疗,治疗组加服莲芪胶囊,对照组加服平消胶囊。结果:治疗组治疗后临床症状积分较对照组显著降低(P<0.05),KPS积分、CD4+、CD4+/CD8+比值、NK细胞数量较对照组显著升高(P<0.05)。结论:莲芪胶囊能增强原发性肝癌患者免疫功能,有效改善患者临床症状。Objective：To observe the efficacy of Lianqi combined with transcatheter hepatic arterial chemoembolization in treatment of primary liver cancer. Methods：98 patients with primary liver cancer in the hospital from January 2010 to October 2012 were divided into treatment group and control group randomly. Both groups were given transcatheter hepatic arterial chemoembolization. 49 cases in the treatment group were given additional Lianqi, while the control group were given additional Ping Xiao capsules. Results：The clinical symptom score of the treatment was significantly lower than the control group after treatment（P〈0.05）, while the KPS, CD4＋,CD4＋/CD8＋ratio, NK cells were significantly higher than the control group（P〈0.05）.Conclusion：Lianqi could not only enhance the immune function in patients with primary liver cancer, but could also improve the clinical symptoms effectively.

关 键 词：莲芪胶囊 肝动脉栓塞化疗 原发性肝癌 

分 类 号：R735.7[医药卫生—肿瘤]